| Name | Title | Contact Details |
|---|
Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The Company specializes in the development and manufacturing of medical devices and has been successfully accessing capital on the public markets as required to finance its operations to date. It is currently preparing for transition to a commercialization phase. Miraculins began as a research and development company in 2002, with a focus on biomarker discovery. In June of 2008, the company shifted its focus to diagnostic asset development where it began to in-license and acquire diagnostic and risk assessment technologies that had completed early stage research and addressed significant unmet medical needs in the U.S., Canada, and global markets.
Clontech Laboratories, Inc. develops, produces, and markets innovative biological products to the life science market worldwide. Clontech is a wholly owned subsidiary of Takara Bio, Inc. Learn more about latest Clontech technologies:
Centerfirst was founded in early 2004 to help healthcare leaders maximize the value of their call centers.
Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.
Prolong is dedicated to the global biotechnology market, and to developing relationships with companies worldwide for raw material supply, commercial development and marketing of its new wave of products - the Supergenerics.